NEW YORK (GenomeWeb News) – Eli Lilly has signed a three-year collaboration with GE Healthcare and GE Global Research to develop in vitro diagnostics to predict the response of patients to targeted cancer therapies, the companies said today.
 
The collaboration covers targeted cancer therapeutics under development at Lilly and GE’s multiplexed tissue-based assays and image analysis tools.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.